

Comparison of clinical outcomes of ultrasonography-guided and blind local injections in facet syndrome: A 6-week randomized controlled trial

Murat Karkucak^a, İbrahim Batmaz^{b,*}, Servet Kerimoglu^c and Ahmet Ayar^d

^aDepartment of Physical Medicine and Rehabilitation, Medical School, Division of Rheumatology Karadeniz Technical University, Farabi Hospital, Trabzon, Turkey

^bDepartment of Physical Medicine and Rehabilitation, Medical School, Dicle University, Diyarbakır, Turkey

^cDepartment Orthopedics and Traumatology, Medical School, Karadeniz Technical University, Trabzon, Turkey

^dDepartment Physiology, Medical School, Karadeniz Technical University, Trabzon, Turkey

Abstract.

BACKGROUND: Facet syndrome is defined as pain that arises from any structure of the facet joints, including the fibrous capsule, synovial membrane, hyaline cartilage, and bone.

OBJECTIVES: To compare the effectiveness of US-guided and blind injections on clinical outcome in facet syndrome.

MATERIALS AND METHODS: Forty-seven patients with the diagnosis of facet syndrome were included. Patients were consecutively randomized into one of the two groups. The patient's history, physical examination and routine laboratory parameters were obtained and diagnosis was established based on physical findings. Two injections (mixture of 2 ml of 1% lidocaine hydrochloride and 20 mg of triamcinolone, to a single or maximum two sites depending on the clinical characteristics of the facet joint) were performed with 15 days apart, a blinded or US-guided manner. Clinical outcome assessments were carried out at 0, 2nd and 6th weeks, using Visual Analog Scale (VAS), Oswestry Disability Index (ODI) and State-Trait Anxiety Inventory (STAI).

RESULTS: The patients' initial VAS and ODI were not significantly different. When the two groups were compared in the 6th week in terms of VAS scores, improvement was more pronounced in the US-guided injection group (US-guided group ($n = 23$) before 7.6 (2.2) cm, after 3.0 (1.7) cm, $P = 0.0001$ vs blind group ($n = 24$) before 7.2 (1.3) cm, after 5.2 (2.0) cm, $P = 0.0001$). The improvement in initial and 6th week ODI was statistically significant in the US-guided injection group ($P = 0.006$). Except STAI I for US-group, trait anxiety scale scores was significant in both groups.

CONCLUSION: The US-guided local injections offer better clinical outcome in the treatment of facet syndrome.

Keywords: Facet joint, injection, ultrasound, low back pain

1. Introduction

Facet syndrome is defined as pain that arises from any structure of the facet joints, including the fibrous

capsule, synovial membrane, hyaline cartilage, and bone. The prevalence rate ranges between 5% and 15% of the population with axial low back pain. Because arthritis is a prominent cause of facet joint pain, the prevalence rate increases with age [1].

Ultrasound (US) is becoming increasingly important in visualizing the musculoskeletal system [2]. It is used as a diagnostic guide and in local injection procedures but is less frequently applied in visualizing deep joints and injections [3]. Local injections are a good alterna-

*Corresponding author: İbrahim Batmaz, Department of Physical Medicine and Rehabilitation, Dicle University Faculty of Medicine, Diyarbakır, Turkey. Tel.: +90 0412 2488001, Gsm: +90 0553 449 0920, Fax: +90 0412 2488001; E-mail: ibrahimbatmaz82@hotmail.com.

14 tive in medical treatment for soft tissue disorders. That
15 effectiveness is enhanced if these are accompanied by
16 imaging. US is a very good guide for local procedures
17 in the musculoskeletal system [2–4].

18 Facet syndrome treatment consists of conservative
19 and interventional approaches [5,6]. Local steroid in-
20 jections are widely used in the treatment of facet syn-
21 drome. This procedure is generally performed accom-
22 panied by fluoroscopy and computerized tomography
23 (CT) [7]. However, these procedures expose patients to
24 radiation and also increase costs [8]. One contempo-
25 rary study compared fluoroscopy and US as guides in
26 steroid injection to the facet joint, and reported similar
27 outcomes from both [9].

28 Well-designed studies are needed for accurate pa-
29 tient selection and the development of appropriate pro-
30 cedures for the application of US in the lumbar region.
31 Therefore, this prospective study was aimed to evalu-
32 ate the effectiveness of US-guided facet joint injections
33 and to compare them with blinding injection in lumbar
34 facet syndrome.

35 2. Material and methods

36 Forty-nine patients diagnosed with facet syndrome
37 were randomized into two groups according to the or-
38 der of admission to the outpatient clinic. A detailed
39 physical examination was performed. Lumbar region
40 movements were measured. Fifteen females and 34
41 males with clinical diagnosis of chronic low back pain
42 were included in our study. Facet joint injection was
43 performed under US to the patients in group I ($n = 23$),
44 whereas blinded injection was done in group II ($n =$
45 24). Two of the patients in group I did not complete the
46 study by their will.

47 The study was approved by the local ethics commit-
48 tee. Written informed consent was obtained from all
49 participants who were included in the study.

50 Inclusion criteria for the study were as follows: pain
51 for at least 6 weeks, pain extending to gluteal region
52 and thigh, presence of pain with lumbar hyperexten-
53 sion and lateral flexion, paravertebral tenderness at the
54 facet joint localization, negative straight leg raising test
55 and normal neurological examination findings [10].

56 The exclusion criteria were as follows: being < 20
57 and ≥ 50 years of age (degenerative osteoarthritis),
58 Body Mass Index (BMI) ≤ 30 kg/m² (because of the
59 difficulty in deep tissue imaging), current anticoagu-
60 lant therapy, malignancy, presence of any scar tissue
61 in the area of application, inflammatory with low back
62 pain, lumbar spine fractures and steroid hypersensitiv-
63 ity.

64 2.1. Blind facet injection procedure

65 A mixture of 2 ml of 1% lidocaine hydrochloride
66 and 20 mg of triamcinolone was injected to maximum
67 two sites, detected by palpation depending on the clini-
68 cal characteristics of the facet joint by 15-day intervals.
69 Patients with single point tenderness received only half
70 a volume of this injection material. This application
71 was performed about 2 cm lateral to the spinous pro-
72 cess at L4-5 level (the line joining the superior as-
73 pect of the iliac crests posteriorly, Tuffier's lines) [11]
74 and 2.5 cm lateral to the spinous process with a 3–
75 5 cm depth at L5-S1 level. These applications were
76 performed by an experienced physiatrist (İ.B.) with 10
77 years' experience in the field of spinal diseases and
78 musculoskeletal interventional procedures.

79 2.2. US evaluation and facet injection procedure

80 All subjects were examined with commercial, real-
81 time equipment (Esaote, Mylab 60, Genoa, Italy) us-
82 ing a 3- to 8-MHz convex transducer following a stan-
83 dardized scanning method. The patient was placed in
84 prone position with a pillow under the abdomen to de-
85 crease lumbar lordosis. Firstly, transverse process was
86 obtained in paramedian sagittal view. Then the probe
87 was moved slightly medial to see the facet joint. The
88 probe was rotated 90 degrees to get the transverse view
89 to scan facet joint better (Fig. 1). Under transverse US
90 imaging of the facet joint, a 22 G spinal needle was
91 inserted lateral to the probe with a 45–60 degrees an-
92 gle using a direct in-plane technique (under aseptic
93 conditions). The needle was advanced until establish-
94 ing contact with the bony surface of the facet joint. If
95 there is one point tender, half of the solution was in-
96 jected [2,12]. US-guided injections were performed by
97 one expert (M.K.).

98 A Visual Analog Scale (VAS) was applied to as-
99 sess pain, and the State-Trait Anxiety Inventory (STAI)
100 form was applied to determine anxiety levels, both be-
101 fore and after injection. The STAI form used was de-
102 veloped to measure anxiety levels in 1964 and adapted
103 into Turkish by Oner et al. [13]. The STAI consists
104 of two subscales measuring state anxiety (STAI-1) and
105 trait anxiety (STAI-2) levels, containing 20 items each.
106 Items take the form of a Likert-type scale. Total scores
107 from both scales range from 20 to 80 [14].

108 The Oswestry Disability Index (ODI) was used to
109 determine the degree of disability. The scale consists of
110 10 items. Each item is rated between 0–5. Total points
111 increases the level of disability increases. The maxi-




Fig. 1. US-guided injection of the right lumbar 4–5 facet joint. Inset shows the positioning of the probe.

num score is 50 points; 31–50 points between severe, moderate between 11–30 points, 1–10 points is considered mild. The disability percentage computed by the percentage of total points system obtained from patients [15].

2.3. Statistical analysis

Compatibility with normal distribution of data obtained by measurement was examined using the Kolmogorov Smirnov test. Student's *t* test was used in the comparison of normally distributed data from the two groups, the Mann Whitney-*U* test for non-normally distributed data, the paired *t* test in the comparison of normally distributed data in repeated measurements within the groups and the Wilcoxon test in the comparison of non-normally distributed data. The chi-squared test was used in the comparison of qualitative data. Measurement data were expressed as mean \pm standard deviation and arithmetical data as percentages (%). Significance was set at $p < 0.05$.

3. Results

The demographic characteristics of the patients are summarized in Table 1.

The baseline VAS values were comparable between the groups ($P = 0.4$). The VAS values were signif-

icantly improved after injection in both groups. But, the improvement in VAS score was better in group I compared to group II [(baseline vs score at 6th week); 7.6(2.2) cm vs 3.0(1.7), $P = 0.0001$ for group 1; 7.2(1.3) cm vs. 5.2 ± 2.0 mm, $P = 0.0001$ for group 2, respectively]. The effect on VAS was time-dependent as the difference between the groups I and II became more significant at 6th week post-injection evaluation (see the methods section and Table 2).

The baseline ODI of the groups were comparable ($P = 0.4$). The ODI were significantly improved after injection in both groups, being more prominent in group I ($P = 0.006$ for group 1; $P = 0.178$ for group II, Table 2).

When the groups were compared with regard to the STAI 2 questionnaire scores; statistically significant improvement was obtained in both groups. However, the improvement in STAI 1 scores was significant only for the group II.

4. Discussion

The results of this study indicates that the US-guided local injections have a potential to provide better clinical outcome in the treatment of facet syndrome as evident by VAS and ODI.

The treatment of facet syndrome consists of conservative and interventional approaches. The interven-

Table 1
The demographic characteristics of the patients

Characteristics	Group I (n = 23)	Group II (n = 24)	P
Age, mean (SD), yrs	38.2(11.6)	37.1(9.1)	0.876
Sex (male/female), n	15/8	17/7	0.337
Physical examination			
Lumbar extension, mean (SD) (°)	27.5(5.3)	26.6(5.3)	0.898
BMI (kg/m ²), mean (SD)	26.7(3.8)	26.0(2.1)	0.580
Injections of level, n			
Unilateral L4-5, L5-S1	13	15	
Unilateral L5-S1	3	1	
Unilateral L4-5	5	4	
Bilateral L5-S1	2	3	
Bilateral L4-L5	–	1	

Values are expressed as mean (standard deviation), BMI; Body mass Index.

Table 2
Comparison of the treatment groups

	Group I (n = 23)	Group II (n = 24)	P
VAS (cm), mean (SD)			
1st injection (initial)			
Before	7.6 (2.2)	7.2 (1.3)	0.400
After	3.5 (1.7)	4.8 (1.4)	0.007
P	0.002	0.018	
2nd injection (2 week)			
Before	4.2 (1.9)	4.8 (1.8)	0.293
After	2.5 (1.8)	3.3 (2.2)	0.196
P	0.000	0.001	
6 week	3.0 (1.7)	5.2 (2.0)	0.001
P*	0.000	0.000	
ODI, mean (SD)			
Initial	69.1 (14.9)	65.3 (13.3)	0.366
6 week	33.3 (14.7)	60.1 (10.2)	0.083
P	0.006	0.178	
STAI (1,2), mean (SD)			
STAI 1			
Before injection	45.1 (10.6)	44.1 (9.5)	0.731
After injection	39.3 (9.4)	39.1 (7.0)	0.958
P	0.135	0.003	
STAI 2			
Before injection	42.5 (5.9)	44.3(5.7)	0.319
After injection	40.2(6.1)	40.3(5.2)	0.902
P	0.000	0.000	

Group I: US-guided injection, Group II: Blind injection, VAS: Visual Analog Scale, STAI: State-trait anxiety inventory, ODI: Oswestry Disability Index. *Initial vs 6. Weeks. Values are expressed as mean (standard deviation). P < 0.05 (significantly) is the significance of values in italics.

162 tional treatment options are injection therapies and
163 radiofrequency treatment [5]. Facet injections are imple-
164 mented for different purposes with different techniques
165 such as diagnostic blocks, intraarticular steroid injec-
166 tion, blocking of the medial branch and blocks before
167 radiofrequency [6]. In our study intraarticular steroid
168 injection was applied to our patients. Pain and disabili-
169 ty scores of patients improved significantly.

170 In a study comparing radiofrequency and injection
171 therapy, injection is proposed as the first choice and if
172 sufficient effect cannot be obtained or the complaints

173 repeat radiofrequency can be the alternative [7]. These
174 applications are commonly performed by fluoroscopy
175 or CT guidance. This increases the patient's exposure
176 to radiation [16]. Moreover, Kim et al. [8] reported
177 emergence of skin lesions after repeated injections ad-
178 ministered under fluoroscopy. This procedure also con-
179 stitutes an additional cost to social security system and
180 time to medical staff. Ha et al. [9] reported the 6-
181 month results of the facet joint injections in 105 pa-
182 tients. In this retrospective study, the preference of US
183 was emphasized due absence of the radiation risk of

184 facet joint blockade, and easy administration in outpa- 235
185 tient clinic as a minimally invasive procedure. Galiano 236
186 et al. [17] had also brought forth that facet joint injec- 237
187 tions with US-guide are easily applicable with mini- 238
188 mal risks. Being radiation-free, cost effective and eas- 239
189 ily repeatable applications which helps to obtain many 240
190 images in multiple planes are the main advantages of 241
191 US [1,3,16]. We also applied the injections in consid- 242
192 eration of similar advantages of ultrasound. 243

193 In a recent study performed by Yun et al. [12], 57 244
194 patients with facet syndrome were randomized into 245
195 two groups. Facet joint injections were applied to one 246
196 group under fluoroscopy and the other group with US 247
197 guidance. Visual Analog Scale, patient's global assess- 248
198 ment and modified ODI were used for the assessment 249
199 of the patients. Significant improvement was shown in 250
200 all parameters within 1 week, 1 month and 3 months. 251
201 However, they did not detect any statistically signifi- 252
202 cant difference between the two methods. Similarly 253
203 in another retrospective study indicated that the US- 254
204 guided procedure did not show significant difference in 255
205 treatment outcomes for pain reduction and functional 256
206 improvements compared with the fluoroscopy-guided 257
207 procedure [18]. In both studies, it was concluded that 258
208 fluoroscopy had no superiority to ultrasound but the ra- 259
209 diation risk of fluoroscopy was emphasized as a disad- 260
210 vantage. 261

211 In one study, the accuracy and clinical efficacy of 262
212 US-guided and blinded-fashion nerve block in lum- 263
213 bar facet joint pain was investigated. They evaluated 264
214 the accuracy of the procedures by confirming the lo- 265
215 cation of needle tip by CT. There were 37 facet joint 266
216 blocks guided by US, in which 32 were correctly tar- 267
217 geted with the first puncture yielding a success rate of 268
218 86.5%. This rate was 31.4% in blinded group. After 269
219 6 weeks of follow-up, the overall remission rates were 270
220 $72.3 \pm 14.0\%$ in US group and $56.7 \pm 11.0\%$ in blind 271
221 injection group [19]. Similarly, in our study, it was con- 272
222 cluded that ultrasound guide facet injection was supe- 273
223 rior in locating the target site than blinded facet injec- 274
224 tion. Also, significant improvement was shown in pain 275
225 reduction and functional improvements in US group. 276
226 In another study involving with non-specific low back 277
227 pain patients, significant reduction in back pain has 278
228 been obtained 3 months after treatment with lidocaine 279
229 alone for 3 weeks to the paravertebral region, while a 280
230 group of the patients received only sham-injection to 281
231 the lumbar region. A significant reduction of pain was 282
232 obtained in both groups [20]. Hence, subjectivity of pa- 283
233 tients satisfaction should be considered when evaluat- 284
234 ing the clinical effectiveness of these procedures. The

235 placebo effect might have contributed to the blinded 236
237 injection group; although its impact on US-guided in- 238
239 jection group could not be ruled out. 240

241 Our study has some limitations. Among these, we 242
243 did not confirm the accuracy of the injection by imag- 244
245 ing of the tip of the needle. However, as mentioned 246
247 above, accuracy of US guided applications has been 248
249 shown with a high rate in several studies [16]. The re- 249
250 search personnel who performed the injections are ex- 250
251 periented in this procedure [2]. The relatively short 251
252 follow-up time of our study is another limitation. 252

253 5. Conclusion

254 Results from this prospective clinical study indicate 255
256 that utilization of US-guidance in local injections offer 256
257 significant potential to improve clinical the outcome in 257
258 the treatment of facet syndrome. Considering the addi- 258
259 tional cost and effectiveness of this procedure, further 259
260 larger scale clinical studies with longer-term follow-up 260
261 are warranted for a more definitive conclusion on the 261
262 use of US-guided injections as a standard protocol for 262
263 facet syndrome management. 263

264 Conflict of interest

265 The authors have no competing interests. 265

266 References

- 267 [1] Shealy CN. Facet denervation in the management of back and 267
268 sciatic pain. *Clin Orthop Relat Res.* 1976; 115: 157-164. 268
- 269 [2] Özçakar L, Kara M, Chang KV, Çarlı AB, Akkaya N, Tok 269
270 F et al. Nineteen reasons why physiatrists should do muscu- 270
271 loskeletal ultrasound: EURO-MUSCULUS/USPRM recom- 271
272 mendations. *Am J Phys Med Rehabil.* 2015; 94: 45-49. 272
- 273 [3] Karkucak M, Kurt M, Özçakar L. Ultrasound Video Demon- 273
274 stration for Lumbar Facet Joint Injection. *American Journal* 274
275 *of Physical Medicine and Rehabilitation.* 2016; 95: 165-166. 275
- 276 [4] Karkucak M, Cilesizoglu N, Capkin E, Can I, Batmaz I, Kerim- 276
277 oğlu S et al. Education and visual information improves ef- 276
278 fectiveness of ultrasound-guided local injections on shoulder 277
279 pain and associated anxiety level: A Randomized controlled 277
280 study. *American Journal of Physical Medicine and Rehabili-* 278
281 *tation.* 2016; 95: 9-14. 278
- 282 [5] Kleef M, Vanelderden P, Cohen SP, Lataster A, Van Zundert 282
283 J, Mekhail N. Pain Originating from the Lumbar Facet Joints. 283
284 *Pain Practice.* 2010; 10: 459-469. 284
- 285 [6] Cohen SP, Huang JHY, Brummet C. Facet joint pain advances 285
286 in patient selection and treatment. *Nature Reviews Rheuma-* 286
287 *tology.* 2013; 9: 101-116. 287

- 280 [7] Civelek E, Cansever T, Kabataş S. Comparison of effective- 305
281 ness of facet joint injection and radiofrequency denervation in 306
282 chronic low back pain. *Turkish Neurosurgery*. 2012; 22: 200- 307
283 206. 308
- 284 [8] Kim HS, Ahn KH, Yun DH, Oh JJ, Jeong YS, Kim DH. Skin 309
285 lesion after repeated fluoroscopically guided procedures: a 310
286 case report. *J Korean Acad Rehab Med*. 2001; 25: 729-733. 311
- 287 [9] Ha DH, Shim DM, Kim TK, Kim YM, Choi SS. Comparison 312
288 of ultrasonography and fluoroscopy-guided facet joint block 313
289 in the lumbar spine. *Asian Spine J*. 2010; 4: 15-22. 314
- 290 [10] Jackson RP, Jacobs RR, Montesano PX. Volvo award in 315
291 clinical sciences. Facet joint injection in low-back pain. A 316
292 prospective statistical study. *Spine*. 1988; 13: 966-971. 317
- 293 [11] Chakraverty R, Pynsent P, Isaacs K. Which spinal levels are- 318
294 identified by palpation of the iliac crests and the posterior su- 319
295 perior iliac spines? *J Anat*. 2007; 210: 232-236. 320
- 296 [12] Yun DH, Kim HS, Yoo DS, Kim DH, Chon JM, Choi SH et 321
297 al. Efficacy of ultrasonography-guided Injections in Patients 322
298 with Facet Syndrome of the Low Lumbar Spine. *Ann Rehabil 323*
299 *Med*. 2012; 36: 66-71. 324
- 300 [13] Oner N, Le Compte A. *A Handbook for State-Trait Anxiety*. 325
301 Istanbul, Turkey, Bogazici University Publication, 1983. 326
- 302 [14] Spielberger CD, Gorsuch RL, Lushene RE. *Manual for the 327*
303 *State-Trait Anxiety Inventory*. Palo Alto, CA, Consulting Psy- 328
304 *chologists Press*, 1970. 329
- [15] Yakut E, Duger T, Oksuz C, Yörükcan S, Ureten K, Turan D, 305
et al. Validation of the Turkish version of the Oswestry Dis- 306
ability Index for patients with low back pain. *Spine*. 2004; 29: 307
581-585. 308
- [16] Wu T, Zhao WH, Dong Y, Song HX, Li JH. Effectiveness of 309
Ultrasound-Guided Versus Fluoroscopy or Computed Tomog- 310
raphy Scanning Guidance in Lumbar Facet Joint Injections in 311
Adults With Facet Joint Syndrome: A Meta-Analysis of Con- 312
trolled Trials. *Arch Phys Med Rehabil*. 2016; 97: 1558-1563. 313
- [17] Galiano K, Obwegeser AA, Walch C, Schatzer R, Ploner F, 314
Gruber H. Ultrasound-guided versus computed tomography- 315
controlled facet joint injections in the lumbar spine: a prospec- 316
tive randomized clinical trial. *Reg Anesth Pain Med*. 2007; 317
32: 317-322. 318
- [18] Han SH, Park KD, Cho KR, Park Y. Ultrasound versus 319
fluoroscopy-guided medial branch block for the treatment of 320
lower lumbar facet joint pain. *Medicine*. 2017; 96: 16. 321
- [19] Wen CB, Li YZ, Sun L, Xiao H, Yang BX, Song L et al. 322
A clinical trial of ultrasound-guided facet joint block in the 323
lumbar spine to treat facet joint-related low back pain. *Sichuan 324*
Da Xue Xue Bao Yi Xue Ban. 2014; 45: 712-716. 325
- [20] Imamura M, Imamura ST, Targino RA, Morales QL, Onoda 326
TLC, Onoda TFG et al. Paraspinal Lidocaine Injection for 327
Chronic Nonspecific Low Back Pain: A Randomized Con- 328
trolled Clinical Trial. *J Pain*. 2016; 17: 569-576. 329